Europe's pharmaceutical innovation crisis demands urgent action. The continent's biopharmaceutical capacity has declined for decades, and now faces accelerating pressure from China's rise and Trump administration policies. Europe's pharma industry risks becoming obsolete without rapid intervention. The sector's challenges stem from interconnected issues: pricing pressures limit R&D investment, manufacturing competitiveness has eroded, and innovation pipelines have weakened relative to global competitors. Recovery is possible but requires immediate strategic reforms. European policymakers and industry leaders must prioritize investment in research infrastructure, streamline regulatory pathways for new drug approvals, and create competitive incentives for pharmaceutical development.
Post from MarketNews_en
Log in to interact with content.